Reading this on a mobile device? Try our optimized mobile version here:

November 1, 2012
Sign upForwardArchive
News for the PBM Industry

  Featured Stories 
  • Analysis finds wide gap in compounding pharmacy oversight
    Compounding pharmacies that have put tainted products on the market have been shut down most often through personal injury lawsuits instead of regulatory action. A former FDA compliance official believes the lack of enforcement might be due to the fact that state pharmacy boards often have members who operate or have interests in compounding pharmacies. USA Today (10/31) LinkedInFacebookTwitterEmail this Story
  • Another compounding pharmacy issues recall
    Ameridose LLC, a sister firm to the troubled New England Compounding Center, recalled all products including two drugs in short supply, one of which is used in critical care. Federal inspectors said the company needs to improve sterility testing. The Wall Street Journal (10/31) LinkedInFacebookTwitterEmail this Story
  Legislative & Regulatory News 
  • Justice Department won't challenge revival of Liberty U.'s ACA suit
    The Obama administration indicated in a Supreme Court filing that it doesn't oppose the revival of a legal challenge against the Affordable Care Act by Liberty University. The lawsuit had been dismissed by the 4th U.S. Circuit Court of Appeals on grounds later overturned in the Supreme Court's health care decision. The Supreme Court will consider whether to let the 4th Circuit consider the merits of Liberty's lawsuit. Reuters (10/31), The Washington Post/The Associated Press (10/31) LinkedInFacebookTwitterEmail this Story
  • More providers to join ACOs next year, poll finds
    Data from a Decisions Resources survey showed nearly a fifth of responding clinicians were part of an accountable care organization in 2012, with many more expected to participate in the coming year. Researchers found that 49% of primary care physician respondents and 53% of endocrinologists were expected to belong to an ACO in the next 12 months. (10/31) LinkedInFacebookTwitterEmail this Story
  Drug Industry Spotlight 
  • Editorial warns Sanofi on drug pricing strategy
    An editorial in The Lancet warned that Lemtrada, Sanofi's experimental multiple sclerosis drug, may be too expensive for patients and payers to afford once it is approved. In September, Sanofi withdrew leukemia drug Campath, which is the same drug at a different dosage, leaving MS patients who had been using it off-label with fewer affordable options. Sanofi provides Campath free to leukemia patients, and analysts said Sanofi withdrew the drug to command a higher price for Lemtrada. Reuters (10/31) LinkedInFacebookTwitterEmail this Story
  • FDA re-examines extended-release generics
    The FDA is taking a closer look at the techniques used by the makers of generic drugs to produce extended-release treatments after Impax Laboratories and Teva Pharmaceuticals' generic bupropion didn't work as well in a 300 mg dose as brand-name depression drug Wellbutrin XL. "This has actually prompted us to change our policy," said Dr. Gregory Geba, head of the FDA's generic drugs office. The New York Times (tiered subscription model) (10/31) LinkedInFacebookTwitterEmail this Story
  Opinion, Commentary & Analysis 
  • Pay-to-delay case works its way toward the Supreme Court
    Courts have held differing opinions on the legality of pay-to-delay deals drugmakers make with competitors to stave off generic competition. The 3rd U.S. Circuit Court of Appeals reversed a trend toward upholding the agreements as legal, making it more likely that the Supreme Court will decide the issue, attorney Erica J. Hemphill Kraus writes. The New England Journal of Medicine (subscription required) (11/1) LinkedInFacebookTwitterEmail this Story
Nature does not equally distribute energy. Some people are born old and tired while others are going strong at 70."
--Dorothy Thompson,
American journalist and radio broadcaster


Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Contact PCMA
Charles Cote
Assistant Vice President, Strategic Communications
(202) 207-3610

Twitter  Follow PCMA on Twitter
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 210 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

 Recent PCMA SmartBrief Issues:   Lead Editor:  Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information